The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study is the first multicenter randomized clinical trial to demonstrate the benefit of corticosteroids in managing macular edema associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The SCORE-CRVO trial has significant clinical impact because it provides the first level 1 evidence to support intervention for visual acuity gain in macular edema with CRVO. The caveat of these findings is that the treatment group had a more significant adverse event profile compared with the observation group, particularly cataract progression and elevated intraocular pressure.
To see more details, visit www.medscape.com
